Unibest

Pharmaceutical intermediates

Seladelpar Intermediates

2 pharmaceutical intermediates for Seladelpar. Indication: Biliary cirrhosis; Cholangitis sclerosans.

提交项目All intermediates

About Seladelpar

Originator
Cymabay Therapeutics Inc
Indication
Biliary cirrhosis; Cholangitis sclerosans
Approved Date
08/14/2024
NCE Patent
08/14/2029
DS/DP
08/02/2025

Available intermediates

2 intermediates currently listed for Seladelpar. Request specifications, documentation or a quotation for any item below.

Seladelpar intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
(S)-2-((4-(TRIFLUOROMETHYL)PHENOXY)METHYL)OXIRANE\ \ \ \ \ \ 256372-58-4\ \ \ \ \ \\ \ \ \ \ \
Ethyl 2-(4-(chlorosulfonyl)-2-methylphenoxy)acetate91427-62-2//

Other programs under S

SaracatinibSarecycline HydrochlorideSarolanerSaxagliptinSeltorexantSemaglutideSitafloxacin hydrate Sofosbuvir

Building toward Seladelpar?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →